Filip Krag Knop has served on scientific advisory panels and/or been part of speakers bureaus for, served as a consultant to, and/or received research support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, Gubra, MedImmune, MSD/Merck, Mundipharma, Norgine, Novo Nordisk, Sanofi, and Zealand Pharma
The tirzepatide constipation treatment guide and tirzepatide diarrhea guide offer practical management strategies for each
Running the numbers through a calculator prevents the kind of mistakes that lead to unexplained lack of results or sudden onset of side effects like headaches
The combination of GIP and GLP-1 agonism is what sets tirzepatide apart from pure GLP-1 agonists like semaglutide
Don't assume you'll figure it out later